CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Aldeyra Therapeutics Requests FDA Transfer Of ADX-2191 Ind Review For PVRL To Division Of Hematologic Malignancies 2 - SEC Filing

By Reuters News

Nov 9 (Reuters) - Aldeyra Therapeutics Inc ALDX.O:

  • ALDEYRA THERAPEUTICS - REQUESTS FDA TRANSFER OF ADX-2191 IND REVIEW FOR PVRL TO DIVISION OF HEMATOLOGIC MALIGNANCIES 2 - SEC FILING

  • ALDEYRA THERAPEUTICS - WITHDRAWS SPECIAL PROTOCOL ASSESSMENT FOR ADX-2191 IN PVRL - SEC FILING

  • ALDEYRA THERAPEUTICS - WHILE JURISDICTIONAL REQUEST IS PENDING, DOES NOT EXPECT TO INITIATE SPA CLINICAL TRIAL FOR ADX-2191 IN PVRL - SEC FILING

  • ALDEYRA THERAPEUTICS - REGULATORY PATH FOR ADX-2191 IN PVRL IS UNCERTAIN AND MAY BE DELAYED - SEC FILING

  • ALDEYRA THERAPEUTICS - EXPECTS CLINICAL PROGRAM FOR ADX-2191 IN PVRL WILL NEED REDESIGN - SEC FILING

Source text: [ID:n0001193125-26-453537]

Further company coverage: ALDX.O

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.